OTCMKTS:ASPCFAcerus Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Acerus Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.04 +0.01 (+19.44 %) (As of 06/4/2020 08:55 AM ET) Add Compare Share Today's Range$0.04Now: $0.04▼$0.0550-Day Range$0.03MA: $0.04▼$0.0552-Week Range$0.02Now: $0.04▼$0.12Volume54,000 shsAverage Volume6,706 shsMarket Capitalization$43.45 millionP/E RatioN/ADividend YieldN/ABeta1.49 ProfileAdvanced ChartCompetitorsEarningsHeadlinesSocial Media Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Acerus Pharmaceuticals. Previous Next 2.2 Community Rank Outperform VotesAcerus Pharmaceuticals has received 4 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAcerus Pharmaceuticals has received 5 “underperform” votes. (Add your “underperform” vote.)Community SentimentAcerus Pharmaceuticals has received 55.56% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Acerus Pharmaceuticals and other stocks. Vote “Outperform” if you believe ASPCF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ASPCF will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAcerus Pharmaceuticals does not currently pay a dividend.Dividend GrowthAcerus Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acerus Pharmaceuticals insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Acerus Pharmaceuticals is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acerus Pharmaceuticals is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.44 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ASPCF Previous Symbol CUSIPN/A CIKN/A Webwww.aceruspharma.com Phone416-679-0771Debt Debt-to-Equity RatioN/A Current Ratio1.23 Quick Ratio1.03Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.77 million Price / Sales11.53 Cash FlowN/A Price / Cash FlowN/A Book Value($0.05) per share Price / Book-0.86Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-16,130,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-119.66%Miscellaneous Employees29 Outstanding Shares1,010,460,000Market Cap$43.45 million Next Earnings Date8/4/2020 (Estimated) OptionableNot Optionable OTC:ASPCF Rates by TradingView Receive ASPCF News and Ratings via Email Sign-up to receive the latest news and ratings for ASPCF and its competitors with MarketBeat's FREE daily newsletter. Acerus Pharmaceuticals (OTCMKTS:ASPCF) Frequently Asked Questions How has Acerus Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Acerus Pharmaceuticals' stock was trading at $0.0380 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ASPCF shares have increased by 13.2% and is now trading at $0.0430. View which stocks have been most impacted by Coronavirus. When is Acerus Pharmaceuticals' next earnings date? Acerus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Acerus Pharmaceuticals. Has Acerus Pharmaceuticals been receiving favorable news coverage? News stories about ASPCF stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Acerus Pharmaceuticals earned a news impact score of -3.2 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. View the latest news aboutAcerus Pharmaceuticals. Who are some of Acerus Pharmaceuticals' key competitors? Some companies that are related to Acerus Pharmaceuticals include Conatus Pharmaceuticals (CNAT), Arbutus Biopharma (ABUS), Theratechnologies (THTX), Zynerba Pharmaceuticals (ZYNE), Evelo Biosciences (EVLO), Cyclerion Therapeutics (CYCN), Savara (SVRA), Axovant Gene Therapies (AXGT), GlycoMimetics (GLYC), SUMMIT THERAPEU/S (SMMT), Helix Biopharma (HBPCF), Theratechnologies (THERF), AVEO Pharmaceuticals (AVEO), Catabasis Pharmaceuticals (CATB) and OASMIA PHARMACE/ADR (OASM). View all competitors. Who are Acerus Pharmaceuticals' key executives? Acerus Pharmaceuticals' management team includes the following people: Dr. Nathan Bryson, Chief Scientific OfficerMr. Philippe Savard, VP, Gen. Counsel & Corp. Sec.Mr. Edward Gudaitis, Pres , CEO & DirectorMr. Robert M. Motz, Chief Financial OfficerMr. Hubert Tomasz Czerwinski, Pres of Acerus Pharmaceuticals SRL What is Acerus Pharmaceuticals' stock symbol? Acerus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ASPCF." How do I buy shares of Acerus Pharmaceuticals? Shares of ASPCF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Acerus Pharmaceuticals' stock price today? One share of ASPCF stock can currently be purchased for approximately $0.04. How big of a company is Acerus Pharmaceuticals? Acerus Pharmaceuticals has a market capitalization of $43.45 million and generates $3.77 million in revenue each year. Acerus Pharmaceuticals employs 29 workers across the globe. What is Acerus Pharmaceuticals' official website? The official website for Acerus Pharmaceuticals is www.aceruspharma.com. How can I contact Acerus Pharmaceuticals? Acerus Pharmaceuticals' mailing address is 2486 Dunwin Drive, Mississauga A6, L5L 1J9. The company can be reached via phone at 416-679-0771 or via email at [email protected] This page was last updated on 6/4/2020 by MarketBeat.com Staff
